Patent intelligence · US
US 11523984
Compositions and methods of administering baclofen
Compositions and methods of administering baclofen
Patent details — US 11523984
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 13, 2022
- Expiration
- Dec 8, 2042
- Applicant
- AMNEAL PHARMACEUTICALS LLC
- Claims
- 14
- CPC classes
- A61K, A61K31/197, A61K9/0019, A61P
Quick answer
US 11523984 (Compositions and methods of administering baclofen) is held by AMNEAL PHARMACEUTICALS LLC. Status: granted. Granted Dec 13, 2022. Expires Dec 8, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AMNEAL PHARMACEUTICALS LLC
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K31/197, A61K9/0019, A61P, A61P1/00
More from AMNEAL PHARMACEUTICALS LLC
Related pharmaceutical patents in our USPTO index.
-
US 12383522
Baclofen formulations and methods of minimizing patient exposure to metabolite variations
granted -
US 12370163
Levodopa dosing regimen
granted -
US 12303482
Levodopa dosing regimen
granted -
US 12303481
Levodopa dosing regimen
granted -
US 12295931
Levodopa dosing regimen
granted -
US 12263149
Levodopa dosing regimen
granted -
US 12263148
Levodopa dosing regimen
granted -
US 12233166
Extended release compositions comprising pyridostigmine
granted
Frequently asked questions
What is US patent 11523984?
US 11523984 (Compositions and methods of administering baclofen) is held by AMNEAL PHARMACEUTICALS LLC. Status: granted. Granted Dec 13, 2022. Expires Dec 8, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11523984?
AMNEAL PHARMACEUTICALS LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 32 pharmaceutical patents for this assignee.
When does US 11523984 expire?
Our index shows an expiration date of Dec 8, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.